Investigating the effect of Plantago psyllium fiber supplementation on levels of cholesterol and inflammation in adolescents with obesity

Submission date	Recruitment status	Prospectively registered
17/08/2020	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
24/08/2020	Completed	[X] Results
Last Edited 19/04/2021	Condition category Circulatory System	[] Individual participant data

Plain English summary of protocol

Background and study aims

Obesity can lead children and adolescents to have an increased risk of developing cardiovascular disease (CVD). A diet supplemented with Plantago psyllium (a type of fiber from the Plantago ovata plant's seeds) has been shown to be effective in reducing certain markers of blood cholesterol and inflammation in adolescents. However, there are no studies that have explored small-dense low-density lipoprotein (sdLDL) nor high-density lipoprotein (HDL) subclasses of cholesterol. The aim of this trial is to assess the impact of a fiber supplement on cholesterol in adolescents with obesity.

Who can participate?

100 adolescents, aged 15 to 19 years old, with obesity will be included in the study.

What does the study involve?

Eligible participants will be randomly allocated to recieve either the Plantago psyllium supplement or an identical dummy pill. These will be taken, dissolved in water, daily over a period of 7 weeks in the morning before food.

What are the possible benefits and risks of participating?

The benefits are the performance of free laboratory tests such as glucose, lipid profile such as cholesterol, triglycerides, insulin and lipoprotein profile with the sub-fractions of HDL and LDL (sdLDL), together with a clinical medical evaluation, which will contribute to the prevention of possible diseases and suggestion of healthy dietary recommendations.

The risks and discomfort that the patient may have are allergy or intolerance to the treatment, an increase in the number of evacuations, and abdominal distension. These side effects would be corrected when the treatment is suspended. Participants or their family members will be advised to suspend treatment if they experience any of these symptoms, and the trial team will determine if any further specific management for the symptoms is needed.

Taking the blood sample involves only the risk of a bruise, which will take between one and two weeks to disappear from the puncture site.

Where is the study run from? Universidad de Guanajuato (Mexico)

When is the study starting and how long is it expected to run for? From February 2017 to March 2020

Who is funding the study?
The University of Guanajuato (Mexico) and Touro University (USA)

Who is the main contact? Patricia González patipili999@gmail.com +52 477 132 91 26

Contact information

Type(s)

Public

Contact name

Dr Patricia González

ORCID ID

https://orcid.org/0000-0002-3401-7519

Contact details

UMAE no 48 IMSS Hospital Avenida México e Insurgentes S/N colonia Los paraísos Leon Mexico 37238 +52 477 717 48 00 ext 31804 patipili999@gmail.com

Type(s)

Public

Contact name

Dr Patricia Sosa

ORCID ID

https://orcid.org/0000-0002-8460-4965

Contact details

UMAE no 48 IMSS Hospital Avenida México e Insurgentes S/N colonia Los paraísos Leon Mexico

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CIBIUG-P40-2017

Study information

Scientific Title

Reduction of small dense LDL and Il-6 after intervention with Plantago psyllium in adolescents with obesity

Acronym

sdLDLpsyllium

Study objectives

Supplementation with Plantago psyllium alone decreases the concentration of sdLDL and inflammation markers (IL-6) in the population at risk such as adolescents with obesity

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Approved 03/08/2018, University of Guanajuato (Calzada de Guadalupe S/N, Zona centro, Guanajuato Gto., México CP 36000; +52 473 73 200 06 ext. 5019); ref: CIBIUG-P40-2017 2. Approved 26/10/2018, Hospital de Gineco-pediatría No. 48 (Av. México e Insurgentes S/N colonia Los insurgentes, León Gto., México CP 37238; +52 477 7-17-48-00), ref: R-2018-1002-052

Study design

Single centre, double-blinded randomized controlled trial

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Cardiovascular disease in adolescents with obesity

Interventions

This study was a randomized placebo-controlled trial with a double-blinded (to the participant and the investigator who gave the treatment) design.

Randomization and allocation to trial group were done using computer random number generation.

All participants were randomized into a 7 week intervention with either 10 g/day of psyllium (equating to 10 g of dietary fiber) Plantago psyllium powder (Kirkland signature ®, Lot 0294B12), or 10 g/day of rice flour placebo (Healthy Flours ® batch AB140119). In both groups, the dose was diluted in 250 ml of water, ingested immediately after dilution with intake of 250 ml of additional water, in the morning, before ingesting food.

The dose of 10 g/day was adopted based on a review of the existing literature, as well as on the volume of fiber and placebo each dose would equate to, so as not to affect compliance with the study protocol.

Both the psyllium and rice flour were packed in opaque bags without labeling the name only as A or B. Each dose was given daily by the blinded investigator.

Adherence to dosing was monitored directly through a checklist and during the weekend through a photograph sent by the participant through What'sApp. Participants were advised to continue their normal eating and exercise patterns during the study period. Three dietary records were collected at baseline and at clinical assessment following the 7 week intervention. Each dietary report encompassed an itemized nutritional intake recorded during two school days and one weekend day. Nutritional intake was recorded using standard household measures, as well as the information from food labels where appropriate. At each visit during the dietary treatment phase, the participants were asked about possible adverse effects or intolerance to psyllium or placebo using an open-ended questionnaire referring to any unusual symptoms or discomfort or side effects such as increased defecation, bloating, flatulence or fullness during the treatment period.

Intervention Type

Supplement

Primary outcome(s)

- 1. Anthropometric and biochemical markers measured using the following at baseline and 7 weeks:
- 1.1. The height and weight of the child measured using a SECA stadiometer (to the nearest 0.1 cm) and a SECA scales (to the nearest 0.1 kg), and body mass index (BMI) was calculated as kilogram per square meter (kg/m2)
- 1.2. Waist circumference (WC) measured using Lufkin ® metallic tape (to the nearest 1mm)
- 1.3. LDL and HDL subclasses measured using a venous blood sample obtained after 12 h of fasting processed using the Lipoprint system (Quantimetrix)
- 1.4. IL-6 measured using an ELISA assay of a venous blood sample was obtained after 12 h of fasting

Key secondary outcome(s))

Somatometric variables measured using the following at baseline and 7 weeks:

- 1.1. Blood pressure measured using an Omron® digital baumanometer
- 1.2. Glucose measured using a venous blood sample obtained after 12 h of fasting processed using enzymatic methods in an autoanalyzer (Spinreact-Spinlab, Model 6002390-412-02)

- 1.3. Homeostatic Model Assessment of Insulin Resistance (HOMA IR) measured using an ELISA assay of a venous blood sample was obtained after 12 h of fasting
- 1.4. Lipid profile measured using a venous blood sample obtained after 12 h of fasting processed using enzymatic methods in an autoanalyzer (Spinreact-Spinlab, Model 6002390-412-02)
- 1.5. The atherogenic index (AI) calculated as total cholesterol/HDL-C using measurements from a venous blood sample obtained after 12 h of fasting processed using enzymatic methods in an autoanalyzer (Spinreact-Spinlab, Model 6002390-412-02) and the Lipoprint system (Quantimetrix)

Completion date

02/03/2020

Eligibility

Key inclusion criteria

- 1. Aged 15 to 19 years
- 2. ≥1 of the following cardiovascular risk factors:
- 2.1. Obesity, defined as a body mass index (BMI) for age more than 2 standard deviations above the median established in the World Health Organization (WHO) Child Growth Standards 2.2. Altered lipid profile, defined as: total cholesterol >70 mg/dl; LDL cholesterol >110 mg/dl; HDL cholesterol <40 mg/dl; fasting glucose >100 mg/dl; elevated triglycerides >90 mg/dl; or insulin resistance with Homeostatic Model Assessment of Insulin Resistance (HOMA IR) >3 3. Non-smokers

Participant type(s)

Other

Healthy volunteers allowed

No

Age group

Child

Lower age limit

15 years

Upper age limit

19 years

Sex

All

Total final enrolment

100

Key exclusion criteria

- 1. Do not agree to adhere to at least 80% of diet and fiber
- 2. Diagnosis of a metabolic and/or infectious disease during the study
- 3. Do not wish to continue in the study or unable to be located for follow up

Date of first enrolment 10/11/2018

Date of final enrolment 15/12/2019

Locations

Countries of recruitmentMexico

Study participating centre Universidad de Guanajuato Calle 20 de Enero 929 Obregon Leon, Guanajuato Mexico 37000

Sponsor information

Organisation

Mexican Social Security Institute

ROR

https://ror.org/03xddgg98

Organisation

Universidad de Guanajuato

ROR

https://ror.org/058cjye32

Funder(s)

Funder type

University/education

Funder Name

Universidad de Guanajuato

Alternative Name(s)

University of Guanajuato, College of the Immaculate Conception, National College of Guanajuato, UG

Funding Body Type

Government organisation

Funding Body Subtype

Universities (academic only)

Location

Mexico

Funder Name

Touro University California

Alternative Name(s)

Touro University, TUC

Funding Body Type

Private sector organisation

Funding Body Subtype

Universities (academic only)

Location

United States of America

Funder Name

Mining Company Santa María de la Paz

Results and Publications

Individual participant data (IPD) sharing plan

Data sets generated and/or analyzed during the current study during this study will be included in the publication of subsequent results.

IPD sharing plan summary

Other

Study outputs

Output type Details
Results article

Date created Date added Peer reviewed? Patient-facing?

01/08/2021 19/04/2021 Yes

No